Endpoints News
Novocure’s glioblastoma fail Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M T W Thu F
18 June, 2026
Manufacturing Day 2026
Biopharma has metabolized the tariff chaos, but the ground keeps shifting under manufacturing and supply chain teams. Hear directly from the experts on what’s changed, what’s working, and what to watch. Join us.
top stories
1. Novocure’s electric fields therapy fails key glioblastoma study
2. Innoviva revives Lyndra's long-acting oral drug platform, with Langer and Woodcock as advisors
3. RA, Forbion and Sanofi Ventures appear to back new eye drug from Korea
4.
news briefing
Pfizer CFO to depart; GSK wins approval for UTI drug
5. Biogen makes up to $1B deal for secretive anti-inflammatory biotech
6. Kardigan raises $400M in IPO to back three clinical-stage cardio drugs
7. Exclusive: Lilly's TuneLab crosses 100-member mark, adds AI models from buzzy startup Chai
8. Antifungal from F2G, Shionogi succeeds in Phase 3 study
9.
peer review
Moderna adds commercial chief, expands Stephen Hoge's role; Reunion Neuroscience CEO departs
more stories
• 
Karen Weintraub
.

Endpoints’ staffers Max Bayer, Ryan Cross, Andrew Dunn and Kyle LaHucik will be at BIO next week. Come say hello if you’re there. Also, Endpoints won’t be sending our usual newsletters tomorrow, because of the Juneteenth federal holiday in the US. We'll be back on Monday, June 22. Enjoy the long weekend!
.
Karen Weintraub
Deputy Editor, Endpoints News
1
by Lei Lei Wu

Novo­cure re­port­edThurs­day morn­ing that its elec­tric fields de­vice com­bined with chemora­di­a­tion failed to ex­tend glioblas­toma pa­tients' lives in a Phase 3 study, damp­en­ing the...

Read the full story
Bob Langer (L) and Janet Woodcock
2
by Kyle LaHucik

A health­care as­set and roy­al­ties hold­ing com­pa­ny is bring­ing a long-act­ing oral med­i­cine ap­proach back to life, res­ur­rect­ing a drug de­liv­ery plat­form that had ac­cu­mu­lat­ed...

Read the full story
3
by Kyle LaHucik

The trend con­tin­ues in which big-name ven­ture in­vestors band to­geth­er to back new com­pa­nies with an ex­per­i­men­tal med­i­cine de­vel­oped by an­oth­er biotech.

RA Cap­i­tal and...

Read the full story
The Endpoints 100: Despite all the turmoil, biotech is having a moment
A year ago, biotech was in its bleakest stretch in a decade. Now IPOs are rebounding and China deals are heating up. John Carroll and a panel of industry leaders dig into the latest Endpoints 100 results and uncover what’s next for the sector.
News Briefing: Quick hits from the biopharma web
4
by ENDPOINTS

Plus news about Apel­lis Phar­ma­ceu­ti­cals, Servi­er, TORL Bio­Ther­a­peu­tics, Ve­rastem, Cor­cept Ther­a­peu­tics, Leg­end Biotech, COUR Phar­ma­ceu­ti­cals, cAMP­field Ther­a­peu­tics and Lab­Ge­nius Ther­a­peu­tics.

👋 Pfiz­er’s CFO will de­part...

Read the full story
5
by Kyle LaHucik

Bio­gen will pay as much as $1 bil­lion — “pre­dom­i­nant­ly” in mile­stone pay­ments — to ac­quire a San Diego biotech that has dis­closed lit­tle about...

Read the full story